Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial.

Nat Commun · 2023 · PMC10287640 · PMID 37349318

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In the subgroup analysis, the addition of bevacizumab showed a trend of improved efficacy (Hazard Ratio [HR] = 0.63 [0.47–0.87] versus 0.74 [0.53–1.04] for patients without bevacizumab), suggesting that adjuvant anti-angiogenic therapy combined with immune checkpoint inhibition warrants further investigation.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.